Cargando…

HeRO®-Graft: technische Anwendung und eigene klinische Erfahrung in 73 Fällen

Increasing age and comorbidities as well as the duration of chronic dialysis make it difficult to establish and maintain a functioning vascular access in patients with terminal kidney failure. The risk of a central venous stenosis or occlusion is greatly increased with a central venous catheter and...

Descripción completa

Detalles Bibliográficos
Autores principales: Harter, Nomita, Mündlein, Eckehard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514814/
https://www.ncbi.nlm.nih.gov/pubmed/34664003
http://dx.doi.org/10.1007/s00772-021-00823-8
_version_ 1784583476700250112
author Harter, Nomita
Mündlein, Eckehard
author_facet Harter, Nomita
Mündlein, Eckehard
author_sort Harter, Nomita
collection PubMed
description Increasing age and comorbidities as well as the duration of chronic dialysis make it difficult to establish and maintain a functioning vascular access in patients with terminal kidney failure. The risk of a central venous stenosis or occlusion is greatly increased with a central venous catheter and cardiological or oncological interventions. The implantation of the Hemodialysis Reliable Outflow (HeRO®) graft (Merit Medical Systems Inc., South Jordan, UT, USA) is meanwhile an established combined interventional/surgical procedure for restoration of the stenosed or occluded venous outflow. In this way the vascular access in the upper extremity can be preserved and the important vascular resource of the lower extremity can be spared. In our center a total of 73 successful implantations have been carried out since 2013. The demand is increasing. With growing clinical experience, the surgical intervention has become an established low risk procedure. According to our clinical experiences, after an implantation a reintervention for acute thrombosis is necessary 2–3 times per year. With appropriate experience revision interventions are usually technically easy to carry out. In cases of complete occlusion of the central venous circulation in the region of the superior vena cava, which cannot be passed by the HeRO® graft, a combined intervention with the Surfacer® System (inside-out procedure) is possible and meaningful. When necessary, the HeRO® graft can also be used with an early cannulation graft in order to avoid a temporary dialysis catheter. Despite the increasing numbers of HeRO® graft implantations, this option remains a reserve procedure in our center. The interventional procedures without implantation of foreign material should first be attempted and established vascular surgical alternatives, such as an internal jugular vein graft should be given priority.
format Online
Article
Text
id pubmed-8514814
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-85148142021-10-14 HeRO®-Graft: technische Anwendung und eigene klinische Erfahrung in 73 Fällen Harter, Nomita Mündlein, Eckehard Gefasschirurgie Leitthema Increasing age and comorbidities as well as the duration of chronic dialysis make it difficult to establish and maintain a functioning vascular access in patients with terminal kidney failure. The risk of a central venous stenosis or occlusion is greatly increased with a central venous catheter and cardiological or oncological interventions. The implantation of the Hemodialysis Reliable Outflow (HeRO®) graft (Merit Medical Systems Inc., South Jordan, UT, USA) is meanwhile an established combined interventional/surgical procedure for restoration of the stenosed or occluded venous outflow. In this way the vascular access in the upper extremity can be preserved and the important vascular resource of the lower extremity can be spared. In our center a total of 73 successful implantations have been carried out since 2013. The demand is increasing. With growing clinical experience, the surgical intervention has become an established low risk procedure. According to our clinical experiences, after an implantation a reintervention for acute thrombosis is necessary 2–3 times per year. With appropriate experience revision interventions are usually technically easy to carry out. In cases of complete occlusion of the central venous circulation in the region of the superior vena cava, which cannot be passed by the HeRO® graft, a combined intervention with the Surfacer® System (inside-out procedure) is possible and meaningful. When necessary, the HeRO® graft can also be used with an early cannulation graft in order to avoid a temporary dialysis catheter. Despite the increasing numbers of HeRO® graft implantations, this option remains a reserve procedure in our center. The interventional procedures without implantation of foreign material should first be attempted and established vascular surgical alternatives, such as an internal jugular vein graft should be given priority. Springer Medizin 2021-10-14 2021 /pmc/articles/PMC8514814/ /pubmed/34664003 http://dx.doi.org/10.1007/s00772-021-00823-8 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Leitthema
Harter, Nomita
Mündlein, Eckehard
HeRO®-Graft: technische Anwendung und eigene klinische Erfahrung in 73 Fällen
title HeRO®-Graft: technische Anwendung und eigene klinische Erfahrung in 73 Fällen
title_full HeRO®-Graft: technische Anwendung und eigene klinische Erfahrung in 73 Fällen
title_fullStr HeRO®-Graft: technische Anwendung und eigene klinische Erfahrung in 73 Fällen
title_full_unstemmed HeRO®-Graft: technische Anwendung und eigene klinische Erfahrung in 73 Fällen
title_short HeRO®-Graft: technische Anwendung und eigene klinische Erfahrung in 73 Fällen
title_sort hero®-graft: technische anwendung und eigene klinische erfahrung in 73 fällen
topic Leitthema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514814/
https://www.ncbi.nlm.nih.gov/pubmed/34664003
http://dx.doi.org/10.1007/s00772-021-00823-8
work_keys_str_mv AT harternomita herografttechnischeanwendungundeigeneklinischeerfahrungin73fallen
AT mundleineckehard herografttechnischeanwendungundeigeneklinischeerfahrungin73fallen